Purpose: Cryoablation (CA) and partial nephrectomy (PN) are effective nephron-sparing treatments for small renal masses. While guidelines list thermal ablation as an option for tumors <3 cm, limited data compare PN and CA in larger tumors. We compared intermediate-term oncologic outcomes between PN and CA in renal masses >3 cm.
Materials And Methods: Patients treated with PN or CA for cT1/cT2, N0M0 renal masses >3 cm between 2006 and 2016 were identified. Propensity score matching was performed in a 1:2 ratio for patients undergoing CA or PN based on age, BMI, Charlson Comorbidity Index (CCI), tumor size, and nephrometry score. Disease-free survival (DFS), metastasis-free survival (MFS), cancer-specific survival (CSS), and overall survival (OS) were estimated using Kaplan-Meier analysis.
Results: One hundred thirteen and 57 patients underwent PN and CA with median follow-up of 4.5 and 3.8 years, respectively. CA was associated with significantly lower 5-year DFS compared to PN (75% vs. 94%, <0.001). Local recurrence was more common after CA compared to PN (5.3% vs. 1.8%). Technical failure occurred with 32% of PCA. However, no significant differences were observed in 5-year MFS (100% for CA vs. 96% for PN, =0.2) or CSS (100% for CA vs. 98% for PN, =0.4).
Conclusions: CA is associated with lower DFS but similar MFS and CSS compared to PN in renal masses >3 cm. CA is a viable option for well-selected patients with comorbidities or high surgical risk, when combined with salvage ablation as indicated.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/JU.0000000000004524 | DOI Listing |
J Urol
March 2025
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Purpose: Cryoablation (CA) and partial nephrectomy (PN) are effective nephron-sparing treatments for small renal masses. While guidelines list thermal ablation as an option for tumors <3 cm, limited data compare PN and CA in larger tumors. We compared intermediate-term oncologic outcomes between PN and CA in renal masses >3 cm.
View Article and Find Full Text PDFWorld J Urol
March 2025
Department of Urology, Zhongda Hospital Southeast University, Nanjing, China.
Purpose: There is very limited evidence on the optimal surgical treatment for patients with larger T2 renal tumors. This study aims to evaluate the oncologic outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) in T2 renal cell carcinoma (RCC).
Methods: A retrospective data analysis was conducted on T2 RCC patients who underwent PN or RN between 2004 and 2019 using the SEER database, and validated with data from multiple centers in China from 2014 to 2019.
Eur Urol Open Sci
March 2025
Dept of Urological Surgery, St. Vincent's University Hospital, Dublin, Ireland.
[This corrects the article .].
View Article and Find Full Text PDFBMC Cancer
March 2025
Department of Urology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi Wu Road, Xin Cheng district, Xi'an, Shaanxi, 710004, China.
Background: The diagnostic criteria for cM0 (i+) stage proposed by American Joint Committee on Cancer (AJCC) in renal cell carcinoma (RCC) still remains unclear. The present study aimed to establish and validate the criteria of cM0 (i+) stage based on postoperative circulating tumor cells (CTCs) monitoring in patients with localized renal cell carcinoma (LRCC).
Materials And Methods: This study enrolled 204 patients with LRCC who received partial or radical nephrectomy from January 2015 to November 2021.
Objective 3D virtual models have gained interest in urology, particularly in the context of robotic partial nephrectomy. From these, newly developed "anatomical digital twin models" reproduce both the morphological and anatomical characteristics of the organs, including the texture of the tissues they comprise. The aim of the study was to develop and test the new digital twins in the setting of intraoperative guidance during robotic-assisted partial nephrectomy (RAPN).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!